Parr Mcknight Wealth Management Group LLC Grows Holdings in Zoetis Inc. $ZTS

Parr Mcknight Wealth Management Group LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS) by 113.8% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 18,191 shares of the company’s stock after acquiring an additional 9,682 shares during the period. Parr Mcknight Wealth Management Group LLC’s holdings in Zoetis were worth $2,150,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Global Wealth Strategies & Associates purchased a new stake in shares of Zoetis in the fourth quarter worth $25,000. Prosperity Bancshares Inc bought a new stake in Zoetis during the fourth quarter valued at about $25,000. Lodestone Wealth Management LLC bought a new stake in Zoetis during the fourth quarter valued at about $30,000. Root Financial Partners LLC lifted its position in shares of Zoetis by 66.5% in the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares in the last quarter. Finally, KERR FINANCIAL PLANNING Corp purchased a new position in shares of Zoetis in the third quarter valued at about $31,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

More Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
• Neutral Sentiment: Multiple law firms, including Rosen, Glancy Prongay, Bragar Eagel & Squire, The Gross Law Firm, Kessler Topaz, Schall, Howard G. Smith, and Bernstein Liebhard, are urging investors who bought ZTS shares during the class period to contact them before the July 27 lead plaintiff deadline.
• Negative Sentiment: A class action lawsuit has been filed against Zoetis and certain officers, with allegations of material misstatements and/or omissions tied to product adoption, which may increase legal costs and pressure the stock. Article Title

Zoetis Stock Performance

NYSE ZTS opened at $75.49 on Monday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. Zoetis Inc. has a 1-year low of $71.47 and a 1-year high of $160.48. The business has a 50 day simple moving average of $79.96 and a two-hundred day simple moving average of $107.64. The stock has a market capitalization of $31.65 billion, a PE ratio of 12.52, a P/E/G ratio of 1.18 and a beta of 0.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s revenue was up 2.9% on a year-over-year basis. During the same period last year, the company earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts predict that Zoetis Inc. will post 6.88 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. Zoetis’s dividend payout ratio is presently 35.16%.

Insider Activity at Zoetis

In other Zoetis news, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The shares were purchased at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Also, Director Michael B. Mccallister bought 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The shares were acquired at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 11,650 shares of company stock valued at $886,384 over the last 90 days. 0.22% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

Several analysts recently issued reports on ZTS shares. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. UBS Group lowered their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. HSBC dropped their price target on Zoetis from $140.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, July 6th. Morgan Stanley reiterated an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a research report on Friday, May 15th. Finally, Citigroup lowered their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Eight investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $123.46.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.